150 related articles for article (PubMed ID: 8341311)
21. Initial clinical experiences with dopamine D2 receptor imaging by means of 2'-iodospiperone and single-photon emission computed tomography.
Yonekura Y; Saji H; Iwasaki Y; Tsuchida T; Fukuyama H; Shimatsu A; Iida Y; Magata Y; Konishi J; Yokoyama A
Ann Nucl Med; 1995 Aug; 9(3):131-6. PubMed ID: 8534585
[TBL] [Abstract][Full Text] [Related]
22. PET studies of dopamine receptor distribution using [18F]fluoroethylspiperone: findings in disorders related to the dopaminergic system.
Wienhard K; Coenen HH; Pawlik G; Rudolf J; Laufer P; Jovkar S; Stöcklin G; Heiss WD
J Neural Transm Gen Sect; 1990; 81(3):195-213. PubMed ID: 2144427
[TBL] [Abstract][Full Text] [Related]
23. Dopamine receptor properties in Parkinson's disease and Huntington's chorea evaluated by positron emission tomography using 11C-N-methyl-spiperone.
Hägglund J; Aquilonius SM; Eckernäs SA; Hartvig P; Lundquist H; Gullberg P; Långström B
Acta Neurol Scand; 1987 Feb; 75(2):87-94. PubMed ID: 2953165
[TBL] [Abstract][Full Text] [Related]
24. PET measurement of D2 and S2 receptor binding of 3-N-[( 2'-18F]fluoroethyl)spiperone in baboon brain.
Coenen HH; Wienhard K; Stöcklin G; Laufer P; Hebold I; Pawlik G; Heiss WD
Eur J Nucl Med; 1988; 14(2):80-7. PubMed ID: 2968911
[TBL] [Abstract][Full Text] [Related]
25. Hemispheric specialization of the basal ganglia during vocal emotion decoding: Evidence from asymmetric Parkinson's disease and
Stirnimann N; N'Diaye K; Jeune FL; Houvenaghel JF; Robert G; Drapier S; Drapier D; Grandjean D; Vérin M; Péron J
Neuropsychologia; 2018 Oct; 119():1-11. PubMed ID: 30040955
[TBL] [Abstract][Full Text] [Related]
26. [The determination of cerebral dopamine (D2) receptor density by using 123I-IBZM-SPECT in Parkinson disease patients].
Hierholzer J; Cordes M; Schelosky L; Barzen G; Poewe W; Henkes H; Keske U; Horowski R; Felix R
Rofo; 1992 Oct; 157(4):390-8. PubMed ID: 1391843
[TBL] [Abstract][Full Text] [Related]
27. PET evaluation of the relationship between D2 receptor binding and glucose metabolism in patients with parkinsonism.
Nakagawa M; Kuwabara Y; Taniwaki T; Sasaki M; Koga H; Kaneko K; Hayashi K; Kira J; Honda H
Ann Nucl Med; 2005 Jun; 19(4):267-75. PubMed ID: 16097635
[TBL] [Abstract][Full Text] [Related]
28. [SPECT and PET in Parkinson's disease].
Matsuda H
Nihon Rinsho; 2000 Oct; 58(10):2000-6. PubMed ID: 11068438
[TBL] [Abstract][Full Text] [Related]
29. The use of PET in Parkinson's disease.
Shinotoh H; Calne DB
Brain Cogn; 1995 Aug; 28(3):297-310. PubMed ID: 8546856
[TBL] [Abstract][Full Text] [Related]
30. Tracing of dopamine receptors in hemiparkinsonism with positron emission tomography (PET).
Rutgers AW; Lakke JP; Paans AM; Vaalburg W; Korf J
J Neurol Sci; 1987 Sep; 80(2-3):237-48. PubMed ID: 3500276
[TBL] [Abstract][Full Text] [Related]
31. Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography.
Brooks DJ; Ibanez V; Sawle GV; Playford ED; Quinn N; Mathias CJ; Lees AJ; Marsden CD; Bannister R; Frackowiak RS
Ann Neurol; 1992 Feb; 31(2):184-92. PubMed ID: 1575457
[TBL] [Abstract][Full Text] [Related]
32. Effect of social status on striatal dopamine D2 receptor binding characteristics in cynomolgus monkeys assessed with positron emission tomography.
Grant KA; Shively CA; Nader MA; Ehrenkaufer RL; Line SW; Morton TE; Gage HD; Mach RH
Synapse; 1998 May; 29(1):80-3. PubMed ID: 9552177
[No Abstract] [Full Text] [Related]
33. Iodine-123-IBF SPECT evaluation of extrapyramidal diseases.
Buck A; Westera G; Sutter M; Albani C; Kung HF; vonSchulthess GK
J Nucl Med; 1995 Jul; 36(7):1196-200. PubMed ID: 7790944
[TBL] [Abstract][Full Text] [Related]
34. PET imaging studies of dopamine D2 receptors: comparison of [18F]N-methylspiperone and the benzamide analogues [18F]MABN and [18F]MBP in baboon brain.
Mach RH; Ehrenkaufer RL; Greenberg JH; Shao L; Morton TE; Evora PH; Nowak PA; Luedtke RR; Cohen D; Reivich M
Synapse; 1995 Mar; 19(3):177-87. PubMed ID: 7784958
[TBL] [Abstract][Full Text] [Related]
35. Brain energy metabolism and dopaminergic function in Huntington's disease measured in vivo using positron emission tomography.
Leenders KL; Frackowiak RS; Quinn N; Marsden CD
Mov Disord; 1986; 1(1):69-77. PubMed ID: 2973559
[TBL] [Abstract][Full Text] [Related]
36. PET demonstrates different behaviour of striatal dopamine D-1 and D-2 receptors in early Parkinson's disease.
Rinne JO; Laihinen A; Någren K; Bergman J; Solin O; Haaparanta M; Ruotsalainen U; Rinne UK
J Neurosci Res; 1990 Dec; 27(4):494-9. PubMed ID: 1981915
[TBL] [Abstract][Full Text] [Related]
37. Human brain receptors, IV. Human in vivo receptor imaging.
Tamminga CA; Conley RR; Wong DF
Am J Psychiatry; 1994 May; 151(5):639. PubMed ID: 8166302
[No Abstract] [Full Text] [Related]
38. Striatal hypometabolism distinguishes striatonigral degeneration from Parkinson's disease.
Eidelberg D; Takikawa S; Moeller JR; Dhawan V; Redington K; Chaly T; Robeson W; Dahl JR; Margouleff D; Fazzini E
Ann Neurol; 1993 May; 33(5):518-27. PubMed ID: 8498828
[TBL] [Abstract][Full Text] [Related]
39. The quantitative analysis of D2-dopamine receptors in baboon striatum in vivo with 3-N-[2'-18F]fluoroethylspiperone using positron emission tomography.
Jovkar S; Wienhard K; Pawlik G; Coenen HH
J Cereb Blood Flow Metab; 1990 Sep; 10(5):720-6. PubMed ID: 2384543
[TBL] [Abstract][Full Text] [Related]
40. [SPECT findings in the hemiparkinson syndrome using 99mTc-HMPAO].
Neumann C; Baas H; Hefner R; Hör G
Nuklearmedizin; 1989 Jun; 28(3):92-4. PubMed ID: 2787025
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
